AbangeLabs6d ago
Trial retention is now an HTA evidence-governance issue: missing outcomes can weaken comparative estimates, utility inputs, and reimbursement models. https://www.mattheneus.com/editorial/trial-retention-outcome-data-completeness-hta-evidence-governance-playbook-2026-04-22 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
Trial retention and outcome-data completeness now need a dedicated HTA governance plan

A 20 April 2026 BMJ Open synthesis of participant reasons for trial non-completion turns retention into a concrete evidence-design problem for health technology assessment. When outcome data go missing, comparative estimates, utility inputs, and reimbursement models all become harder to defend.

AbangeLabs Editorial
Show threadundjetztApr 25
@langhaarschneider jetzt werde ich sentimental. Vor über 20 Jahren für ein Solokonzert von #justinSullivan von #nma nach Hall ins Anlagencafe gefahren. Unvergessener Abend.
ZorroApr 4

Enjoyed the Hallyu - The Korean Wave exhibition at the National Museum this morning. A history lesson and a 90s explosion of pop culture with music, film and fashion artefacts on display.

https://www.nma.gov.au/hallyu/exhibition

Then, it was off to the Australian Scrabble championships to see how serious Scrabblers get their Scrabble on.

#canberra #scrabble #hallyu #nma

AbangeLabsApr 2
HTA evidence teams are hitting a fragmentation wall: ITC, MAIC, NMA, RWE, modelling, and reporting now need one traceable workflow, not stitched-together handoffs. https://www.mattheneus.com/editorial/abangelabs-hta-studio-itc-foundation-end-to-end-hta-evidence-platform-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #HealthEconomics
AbangeLabs HTA Studio: From ITC Foundation to End-to-End HTA Evidence Platform

Health technology assessment (HTA) evidence teams are increasingly asked to deliver multi-method evidence packages spanning indirect treatment comparison (ITC), matching-adjusted indirect comparison (MAIC), network meta-analysis (NMA), economic modelling, and reporting. This article examines why fragmented execution is becoming a methodological governance risk and how AbangeLabs HTA Studio addresses that problem through documented current capabilities.

AbangeLabs Editorial
AbangeLabsApr 2
G-BA says concizumab's added benefit is not proven in haemophilia A because comparator alignment still decides whether evidence lands or unravels. https://www.mattheneus.com/editorial/g-ba-concizumab-haemophilia-a-added-benefit-not-proven-comparator-mismatch-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis
German Federal Joint Committee (G-BA) says concizumab added benefit is not proven in haemophilia A

On 19 March 2026, the German Federal Joint Committee (G-BA) concluded that concizumab added benefit is not proven for routine prophylaxis of bleeding in people aged 12 years and older with severe haemophilia A and no factor VIII inhibitors. The core issue was evidence architecture, not a failed positive trial: the submitted package did not provide a relevant comparison against factor VIII prophylaxis or emicizumab, and no accepted indirect treatment comparison supported the claim.

AbangeLabs Editorial
AbangeLabsApr 2
NICE’s fezolinetant decision is a live case study in how reimbursement can clear despite uncertain indirect evidence beyond placebo. The real lesson is comparator-bridge discipline, not false certainty. https://www.mattheneus.com/editorial/nice-fezolinetant-menopause-final-guidance-indirect-comparison-uncertainty-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
National Institute for Health and Care Excellence (NICE) clears fezolinetant when hormone replacement therapy is unsuitable

On 31 March 2026, the National Institute for Health and Care Excellence (NICE) published final guidance TA1143 recommending fezolinetant for moderate to severe vasomotor symptoms associated with menopause when hormone replacement therapy is unsuitable.

AbangeLabs Editorial
AbangeLabsApr 1
When two NMAs disagree, the ranking usually isn’t the truth—it’s the output of study selection, population splits, and consistency choices. This playbook shows how to stress-test the decision question before a league table enters a dossier. https://www.mattheneus.com/editorial/when-two-nmas-disagree-similarity-consistency-governance-playbook-2026-04-01 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
When two network meta-analyses disagree: a playbook for similarity, consistency, and ranking discipline

A new commentary in the Journal of the European Academy of Dermatology and Venereology uses two recent hidradenitis suppurativa network meta-analyses as a warning against overinterpreting treatment rankings. For HTA, market access, and evidence teams, the operational lesson is clear: lock the decision question first, document similarity and inconsistency checks explicitly, and show how network design choices change the answer before a ranking enters a dossier.

AbangeLabs Editorial
AbangeLabsMar 30

HAS France NMA Acceptability Framework: A Cross-Agency Evidence Planning Playbook.

https://www.mattheneus.com/editorial/fallback-canary-has-france-nma-acceptability-framework-evidence-planning-playbook-2026-03-27

#HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis

HAS France NMA Acceptability Framework: A Cross-Agency Evidence Planning Playbook

France's Haute Autorité de Santé (HAS) publishes explicit validity conditions for indirect treatment comparison (ITC) evidence that diverge from the binary RCT-only stance historically associated with German AMNOG. Understanding these conditions — and how they intersect with IQWiG and NICE methodology — is one of the highest-leverage planning activities a global evidence team can perform. This playbook maps the HAS acceptability framework for network meta-analysis (NMA) evidence, compares it…

AbangeLabs Editorial
AbangeLabsMar 30

Bridging HAS and IQWiG Evidence Standards: A Cross-Border Network Meta-Analysis Planning Playbook.

https://www.mattheneus.com/editorial/fallback-canary-has-iqwig-cross-border-nma-evidence-planning-playbook-2026-03-26

#HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis

Bridging HAS and IQWiG Evidence Standards: A Cross-Border Network Meta-Analysis Planning Playbook

France and Germany impose distinct but reconcilable methodological requirements on indirect treatment comparison evidence. This playbook maps the divergences between HAS and IQWiG and provides an actionable architecture for building a single NMA and MAIC evidence package that satisfies both national agencies — reducing submission rework and eliminating cross-dossier inconsistency risk.

AbangeLabs Editorial
AbangeLabsMar 30

MHRA's patient-information modernisation and device advice refresh set a new evidence-operations baseline.

https://www.mattheneus.com/editorial/mhra-improving-patient-information-device-regulatory-advice-evidence-operations-playbook-2026-03-19

#HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis

MHRA's patient-information modernisation and device advice refresh set a new evidence-operations baseline

MHRA updates published between 12 and 18 March 2026 indicate a tighter operational cadence for patient information and medical device regulatory advice. This playbook translates those signals into concrete evidence-governance actions for HTA and market access teams.

AbangeLabs Editorial